Alterity completes Placement Tranche 1 raising $10M
$25M Second Tranche to complete following shareholder approval Alterity completes Tranche 1 of Placement raising $10M Tranche 2 completes on
Read More
Alterity Therapeutics is developing best-in-class therapies to treat neurodegenerative disease.
The Company was incorporated in 1997 in Melbourne, Australia and listed on the Australian Securities Exchange in 2000 and NASDAQ in 2002
The company operates under the tickers ASX: ATH and NASDAQ: ATHE.
Investment Highlights
- Strong and highly experienced board and management team with significant R&D and commercialisation experience including 3 drug approvals by US FDA.
- ATH434 is a novel drug candidate targeting key proteins implicated in neurodegeneration of Parkinson’s disease and atypical parkinsonism.
- ATH434 has completed its Phase 1 clinical trial program.
- First therapeutic target selected – Multiple System Atrophy (MSA), a form of atypical parkinsonism, is a devastating disease with no approved treatments.
- FDA Orphan Drug designation in the U.S. and EU for ATH434 for the treatment of MSA received.
- Significant market potential in MSA – estimated peak sales of US$725M.
Investor Resources
Company presentations
| May 22, 2020 | Alterity Therapeutics AAN Presentation – May 2020 | 402 KB | |
| November 26, 2019 | AGM Presentation 2019 | 777 KB | |
| June 4, 2019 | Alterity Therapeutics Investor Presentation for FNN | 1 MB | |
| May 9, 2019 | Alterity Therapeutics AAN Presentation | 755 KB | |
| April 10, 2019 | Alterity Therapeutics Investor Presentation | 2 MB | |
| January 8, 2018 | Prana Biotechnology JPM investor presentation | 3 MB | |
| January 8, 2018 | Biotech Showcase Presentation | 3 MB | |
| January 8, 2018 | Biotechnology Biotech Showcase Investor Presentation | 3 MB | |
| April 22, 2016 | World Orphan Drug Congress Presentation | 3 MB | |
| July 17, 2014 | AAIC Panel Presentation – Colin Masters | 3 MB | |
| February 18, 2014 | Reach2HD Clinical Results Investor Presentation | 1 MB |
ASX Announcements
2020
2019
2018
| February 10, 2019 | Appendix 3B – Cleansing Notice – Feb 2018 | 362 KB | |
| January 7, 2019 | Form 603 – Notice of Initial Substantial Holder Morgan Stanley – Jan 2018 | 543 KB | |
| January 7, 2019 | Form 603 – Notice of Initial Substantial Holder MUFG – Jan 2018 | 457 KB | |
| January 7, 2019 | Appendix 3B – Jan 2018 | 955 KB | |
| December 23, 2018 | PBT Trading Halt – Dec 2018 | 459 KB | |
| December 4, 2018 | Form S-8 Dec 2018 | 271 KB | |
| November 19, 2018 | Appendix 3B – Nov 2018 | 940 KB | |
| November 19, 2018 | Appendix 3Y Change of Director’s Interest Notice – Nov 2018 | 456 KB | |
| November 16, 2018 | Results of AGM 2018 | 186 KB | |
| November 16, 2018 | AGM Presentation – Nov 2018 | 621 KB | |
| October 16, 2018 | Notice of AGM – Oct 2018 | 849 KB | |
| July 16, 2018 | Appendix 3B and 708A Notice – Jul 2018 | 248 KB | |
| June 27, 2018 | Investor Presentation – Jun 2018 | 5 MB | |
| January 22, 2018 | Appendix 3B – Jan 2018 | 809 KB |
Financial reports
2020
| September 16, 2020 | Form 20-F 2020 | 2 MB | |
| September 9, 2020 | Appendix 4G Ended 30 June 2020 | 374 KB | |
| September 9, 2020 | Annual Report 2020 | 2 MB | |
| August 31, 2020 | Appendix 4E Year ended 30 June 2020 | 454 KB | |
| July 30, 2020 | Appendix 4C – June 2020 | 384 KB | |
| April 30, 2020 | Appendix 4C – March 2020 | 346 KB | |
| February 28, 2020 | Form 6-K Feb 2020 | 233 KB | |
| February 28, 2020 | Appendix 4D 2019 | 410 KB | |
| January 31, 2020 | Appendix 4C – December 2019 | 372 KB |
2019
| October 30, 2019 | Appendix 4C – September 2019 | 346 KB | |
| September 2, 2019 | Form 20-F 2019 | 828 KB | |
| August 30, 2019 | Appendix 4G FY Ended 2019_06_30 | 341 KB | |
| August 30, 2019 | Annual Report 2019 | 1 MB | |
| August 1, 2019 | Appendix 4C – June 2019 | 151 KB | |
| May 13, 2019 | Form-6-K-2019_03_01 | 400 KB | |
| April 16, 2019 | Appendix 4C – Mar 2019 | 161 KB | |
| February 28, 2019 | Form 6-K – Mar 2019 | 400 KB | |
| February 28, 2019 | Appendix 4D 2018 | 217 KB | |
| January 31, 2019 | Appendix 4C – Dec 2018 | 234 KB |
2018
| May 13, 2019 | Form 6-K Feb 2018 | 148 KB | |
| October 30, 2018 | Appendix 4C – Sept 2018 | 170 KB | |
| September 3, 2018 | Form 20F – 2018 | 2 MB | |
| August 31, 2018 | Appendix 4G FY Ended 2018_06_30 | 123 KB | |
| August 31, 2018 | Annual Report 2018 | 2 MB | |
| July 30, 2018 | Appendix 4C – Jun 2018 | 262 KB | |
| May 7, 2018 | Appendix 4C – Mar 2018 | 263 KB | |
| March 4, 2018 | Form 6-K Feb 2018 | 148 KB |
Corporate governance
| May 15, 2019 | ATH Constitution | 414 KB | |
| May 15, 2019 | Diversity Policy | 197 KB | |
| May 15, 2019 | Securities Trading Policy | 343 KB | |
| May 15, 2019 | Whistle Blower Policy | 320 KB | |
| August 30, 2019 | ATH – Corporate Governance Statement 2019 | 147 KB | |
| April 29, 2020 | Board Charter | 1 MB | |
| July 23, 2020 | PBT 2004 EMPLOYEES’, DIRECTORS’ AND CONSULTANTS’ SHARE AND OPTION PLAN | 88 KB | |
| July 23, 2020 | PBT 2018 AMERICAN DEPOSITARY SHARE (ADS) OPTION PLAN | 205 KB |
News
Alterity raises $35M in placement to international and Australian institutions and sophisticated investors.
Successfully obtained binding commitments for A$35M via institutional placement to be settled in 2 tranches Tranche 1: $10M raised under Alt
Read MoreNew data independently confirms and extends laboratory findings and expands safety profile of ATH434
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) today announced that new clinical and experimental phar
Read MoreAlterity Therapeutics meeting with US FDA provides development pathway for ATH434
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is pleased to announce that it has received guidance fr
Read MoreAlterity Therapeutics presents data on ATH434 to the American Academy of Neurology
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has presented data on ATH434 (formerly PBT434) for the
Read MoreAlterity receives a $4.8 million R&D Tax Incentive Refund
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced that it has received a A$4.
Read MoreEuropean Commission approves Orphan Designation for Alterity’s lead drug candidate
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) announces that the European Commission (EC) has
Read MoreAlterity’s lead drug candidate receives positive opinion from European medical agency
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has received a positive opinion from the Europe
Read MoreAlterity presents clinical data on PBT434 at the 2019 MDS Congress
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), presents a poster today titled: A First in Hum
Read MoreAlterity Therapeutics to Present at the Janney Healthcare Conference in New York
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) is participating in the Janney Healthcare Confe
Read MoreQuarterly Cash Flow Report
Highlights: Completion of Phase 1 Clinical Trial; PBT434 found to be safe and well-tolerated; clinically tested doses achieve concentrations
Read MoreAlterity Therapeutics Announces Successful Completion of Phase 1 Clinical Trial
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) today announced that it has successfully comple
Read More
Alterity Therapeutics talks to Finance News Network
Alterity Therapeutics Limited (ASX:ATH) CEO & Chairman, Geoffrey Kempler, discusses the company’s development pipeline and lead drug
Read MoreReceive news from Alterity Therapeutics
